Kyowa Kirin Co., Ltd.: Parkinson Disease trials

The registry lists 28 Parkinson Disease studies with Kyowa Kirin Co., Ltd. as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 5Phase 2 10Phase 3 13No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedNCT02610231Phase 3Results posted
• A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedNCT01968031Phase 3Results posted
• An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001TerminatedNCT00199381Phase 3Results posted
• A Through QT/QTc Study of KW-6356CompletedNCT04342273Phase 1
• A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinCompletedNCT04070495Phase 1
• A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinCompletedNCT03970798Phase 1
• A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsCompletedNCT03830528Phase 1
• A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsCompletedNCT03703570Phase 2
• A Study of KW-6356 in Subjects With Early Parkinson's DiseaseCompletedNCT02939391Phase 2
• The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.CompletedNCT02174250Phase 1
• Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease PatientsCompletedNCT02073981
• Extended Long-Term Safety Study of KW-6500CompletedNCT01063621Phase 3
• Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500CompletedNCT01058291Phase 3
• Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease PatientsCompletedNCT00957203Phase 3
• Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00955526Phase 3
• Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseaseCompletedNCT00955318Phase 3
• A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyCompletedNCT00955045Phase 2/3
• Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyCompletedNCT00610103Phase 2
• 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaCompletedNCT00456794Phase 2
• 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaCompletedNCT00456586Phase 2
• A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00455507Phase 2
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseCompletedNCT00250393Phase 2
• A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsCompletedNCT00199433Phase 2
• A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaCompletedNCT00199420Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00199407Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseCompletedNCT00199394Phase 3
• An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018CompletedNCT00199368Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00199355Phase 2